Multiple Sclerosis: The Accelerated Cure Project for Multiple Sclerosis

Current Treatments
BETASERON® (interferon beta-1b) is indicated for the treatment of relapsing forms of multiple sclerosis to reduce the frequency of clinical exacerbations. Patients with multiple sclerosis in whom efficacy has been demonstrated include patients who have experienced a first clinical episode and have MRI features consistent with multiple sclerosis

AVONEX® (Interferon beta-1a) is a 166 amino acid glycoprotein with a predicted molecular weight of approximately 22,500 daltons. It is produced by recombinant DNA technology using genetically engineered Chinese Hamster Ovary cells into which the human interferon beta gene has been introduced. The amino acid sequence of AVONEX® is identical to that of natural human interferon beta.

COPAXONE is the brand name for glatiramer acetate (formerly known as copolymer-1). Glatiramer acetate, the active ingredient of COPAXONE, consists of the acetate salts of synthetic polypeptides, containing four naturally occurring amino acids: L-glutamic acid, L-alanine, L-tyrosine, and L-lysine with an average molar fraction of 0.141, 0.427, 0.095, and 0.338, respectively. The average molecular weight of glatiramer acetate is 5,000 – 9,000 daltons. Glatiramer acetate is identified by specific antibodies.

Rebif® (interferon beta-1a) is a purified 166 amino acid glycoprotein with a molecular weight of approximately 22,500 daltons. It is produced by recombinant DNA technology using genetically engineered Chinese Hamster Ovary cells into which the human interferon beta gene has been introduced. The amino acid sequence of Rebif® is identical to that of natural fibroblast derived human interferon beta. Natural interferon beta and interferon beta-1a (Rebif®) are glycosylated with each containing a single N-linked complex carbohydrate moiety.

Tysabri is a monoclonal antibody that affects the actions of the body's immune system. Monoclonal antibodies are made to target and destroy only certain cells in the body. This may help to protect healthy cells from damage. Tysabri is used to treat relapsing forms of multiple sclerosis.

Gilenya™ is a new class of medication called a phingosine 1-phosphate receptormodulator, which is thought to act by retaining certain white blood cells (lympohcytes) in the lymph nodes, thereby preventing those cells from crossing the blood-brain barrier into the central nervous system (CNS). Preventing the entry of these cells into the CNS reduces inflammatory damage to nerve cells.

Early Symptoms
The most common early symptoms of MS include:
* Tingling * Numbness
* Loss of balance
* Weakness in one or more limbs
* Blurred or double vision

Less common symptoms of MS may include
* Slurred speech
* Sudden onset of paralysis
* Lack of coordination
* Cognitive difficulties

Listed above, the early symptoms. I tend to be a poster child for these. The symptoms that occur later on are too numerous just to list. There will be a link included that will get you to a site where these symptoms are listed and explained. Keep in mind that someone may have some of these or many of these, there is no way to tell.

Multiple sclerosis statistics show that approximately 250,000 to 350,000 people in the United States have been diagnosed with this disease. The life expectancy for people with multiple sclerosis is nearly the same as for those without MS. Because of this, multiple sclerosis statistics place the annual cost of MS in the United States in the billions of dollars. MS is five times more prevalent in temperate climates -- such as those found in the northern United States, Canada, and Europe -- than in tropical regions. Furthermore, the age of 15 seems to be significant in terms of risk for developing the disease. Some studies indicate that a person moving from a high-risk (temperate) to a low-risk (tropical) area before the age of 15 tends to adopt the risk (in this case, low) of the new area and vice versa. Other studies suggest that people moving after age 15 maintain the risk of the area where they grew up.

The National MS Society

Sunday, October 4, 2009

The Accelerated Cure Project for Multiple Sclerosis

The Accelerated Cure Project for Multiple Sclerosis is a national nonprofit organization dedicated to curing Multiple Sclerosis (MS) by determining the cause of MS.

We believe the route to finding the cure will most quickly come from determining the cause or causes of MS. The causes will be found by developing a logical, organized, straight-forward process based on what is known about the causes of disease in general. This process must be clearly spelled out and presented in a manner that is accessible to those involved: researchers, clinicians, and individuals with MS.

We call the plan that is emerging from this process the "Cure Map."

The development and execution of the Cure Map is supported by:

A top notch Scientific Advisory Board
An Information Portal to distribute information on MS, the Cure Map, and related materials
Fundraising efforts to pay for the development of the Cure Map
A Community, both online and off, of our constituency
Our constituency includes:

Individuals with MS and their families - Involving and educating those who are most affected by MS as to what is known, what is being done, and what should be done is critical. Ultimately it is people with MS and their loved ones who are responsible for promoting the efforts for a cure.

Clinicians treating individuals with MS and researchers working on areas related to MS - We collect all the news and information on MS that we can. We make this information available in a single, easy-to-use forum called MSNews so that it is not difficult to keep up to date with what is happening in the world of MS.

Other nonprofit MS organizations - We share our research, framework, and technology with any organization who can help people with MS. It is important for any beneficial information or technology to reach as many people as necessary.

No comments:

Subscribe to: Post Comments (Atom)